Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Overview of Cd24 As a New Molecular Marker in Ovarian Cancer Publisher Pubmed



Tarhriz V1 ; Bandehpour M2 ; Dastmalchi S3, 4 ; Ouladsahebmadarek E5 ; Zarredar H6 ; Eyvazi S2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Molecular Medicine Research Center, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
  2. 2. Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Biotechnology Research Center, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran
  4. 4. Faculty of Pharmacy, Near East University, Nicosia, North Cyprus, Turkey
  5. 5. Women’s Reproductive Health Research Center, Clinical Institute, Tabriz University of Medical Sciences, Tabriz, Iran
  6. 6. Tuberculosis and Lung Disease Research Center, Clinical Institute, Tabriz University of Medical Science, Tabriz, Iran

Source: Journal of Cellular Physiology Published:2019


Abstract

Ovarian cancer (OC) is the fifth leading cause of cancer-related death among women. The high mortality rate is due to lack of early symptoms, late diagnosis, limited treatment options, and also emerging of drug resistance. Todays, molecular markers have become promising in tumor-targeted therapy. Several molecular markers have been known in OC immunotherapy. Identification of the specific molecular markers with prognostic significance is interested. CD24 is a small sialoglycoprotein which is localized in lipid rafts through its glycosylphosphatidylinositol (GPI) anchor. It has been reported that CD24 is overexpressed in many cancers including OC. Also, CD24 is identified as a cancer stem cell marker in OC. The CD24 expression is associated with the development, invasion, and metastasis of cancer cells. The exact role of CD24 in cancer cells is not clearly understood. Recently, CD24 has been identified as an independent prognostic marker of survival in patients with OC. In this study, we reviewed the molecular targets in OC immune-targeted therapy and also presented an overview of the new molecular marker CD24 and its association with the OC by reviewing the recent literature. © 2018 Wiley Periodicals, Inc.
Related Docs
View other Related Docs
1. Involvement of Cd24 in Multiple Cancer Related Pathways Makes It an Interesting New Target for Cancer Therapy, Current Cancer Drug Targets (2018)
2. Bevacizumab Antibody Affinity Maturation to Improve Ovarian Cancer Immunotherapy: In Silico Approach, International Journal of Peptide Research and Therapeutics (2019)
3. Identification of a Novel Single Chain Fragment Variable Antibody Targeting Cd24-Expressing Cancer Cells, Immunology Letters (2017)
4. Differential Expression Analysis in Epithelial Ovarian Cancer Using Functional Genomics and Integrated Bioinformatics Approaches, Informatics in Medicine Unlocked (2023)
5. Immune Therapy of Melanoma: Overview of Therapeutic Vaccines, Journal of Cellular Physiology (2019)
6. Anti-Cancer Therapeutic Strategies Based on Hgf/Met, Epcam, and Tumor-Stromal Cross Talk, Cancer Cell International (2022)
7. Ovarian Cancer in the World: Epidemiology and Risk Factors, International Journal of Women's Health (2019)
8. Dacomitinib, a Pan-Inhibitor of Erbb Receptors, Suppresses Growth and Invasive Capacity of Chemoresistant Ovarian Carcinoma Cells, Scientific Reports (2017)
Experts (# of related papers)
View all Related Experts
Seyed Hamidollah Ghaffari (3)
Nima Rezaei (2)
Other Related Docs
9. Antibody-Drug Therapeutic Conjugates: Potential of Antibody-Sirnas in Cancer Therapy, Journal of Cellular Physiology (2019)
10. Effects of Silibinin on Growth and Invasive Properties of Human Ovarian Carcinoma Cells Through Suppression of Heregulin/Her3 Pathway, Tumor Biology (2016)
11. Anti-Tumour Activity of Tivozanib, a Pan-Inhibitor of Vegf Receptors, in Therapy-Resistant Ovarian Carcinoma Cells, Scientific Reports (2017)
12. Catalase Application in Cancer Therapy: Simultaneous Focusing on Hypoxia Attenuation and Macrophage Reprogramming, Biomedicine and Pharmacotherapy (2022)
13. Angioregulatory Role of Mirnas and Exosomal Mirnas in Glioblastoma Pathogenesis, Biomedicine and Pharmacotherapy (2022)
14. Platinum-And Non-Platinum-Based Chemotherapy in Patients With Recurrent Platinum-Resistant Ovarian Cancer: A Review Article, Journal of Obstetrics# Gynecology and Cancer Research (2024)
15. Targeting Cancer Stem Cell-Specific Markers And/Or Associated Signaling Pathways for Overcoming Cancer Drug Resistance, Tumor Biology (2016)
16. Current Trends in Targeted Therapy for Drug-Resistant Infections, Applied Microbiology and Biotechnology (2019)
17. Glance Into Cancer Stem Cells, Journal of Kerman University of Medical Sciences (2016)
18. Micrornas in Breast Cancer: Roles, Functions, and Mechanism of Actions, Journal of Cellular Physiology (2020)
19. Cd44 and Cd74: The Promising Candidates for Molecular Targeted Therapy in Oral Squamous Cell Carcinoma, Dental Research Journal (2015)
20. Clinical Efficacy and Safety of Bispecific Antibodies for the Treatment of Solid Tumors: A Systematic Review and Meta-Analysis, Expert Review of Anticancer Therapy (2023)
21. Antibody Based Epcam Targeted Therapy of Cancer, Review and Update, Current Cancer Drug Targets (2018)
22. Bevacizumab Inhibits Angiogenic Cytokines in Head and Neck Squamous Cell Carcinoma: From Gene to the Protein, International Journal of Hematology-Oncology and Stem Cell Research (2018)
23. Specific Immunotherapy in Ovarian Cancer: A Systematic Review, Immunotherapy (2016)
24. Teeth-Derived Stem Cells: A Source for Cell Therapy, Journal of Cellular Physiology (2019)